Huang Lab to Present Preclinical PH102 Data at the 2024 San Antonio Liver Cancer Symposium
SAN ANTONIO, Texas — The Huang Lab at the Mays Cancer Center at UT Health San Antonio will present new preclinical data on PH102 at the 2024 San Antonio Liver Cancer Symposium. Dr. Gang Huang will deliver a seminar talk. Vincent Pham, Cancer Biology PhD Candidate, will present a poster highlighting complementary results.
PH102 is a GPC3‑targeted CAR T‑cell therapy in development for hepatocellular carcinoma. The preclinical program evaluates strategies to improve T‑cell activity and durability in the tumor microenvironment.
“Our team is building a clear translational path for PH102,” said Dr. Huang. “We are excited to share progress with the liver cancer community in San Antonio.”
“We look forward to feedback from clinicians and researchers,” said Pham. “These discussions will help shape the next phase of development.”
The San Antonio Liver Cancer Symposium is hosted by the Mays Cancer Center. The meeting gathers global experts to discuss advances in liver cancer research and care.
About the Huang Lab
The Huang Lab at UT Health San Antonio is a basic and translational cancer research group within the MD Anderson Mays Cancer Center at UT Health San Antonio. Our team integrates hematology and solid tumor biology with immunology and metabolism to uncover mechanisms and design interventions. We advance cell and biologic therapies, including CAR T‑cell approaches for solid tumors. We also conduct research in trauma and military health. We move discoveries toward clinical impact through product development and collaborations with clinicians and industry. Education and mentorship are core to our mission. We train students, postdoctoral fellows, and early‑career scientists in rigorous, multidisciplinary research. Together, we aim to deliver therapies and technologies that improve patient outcomes.